ORIGINAL RESEARCH article

Front. Neurosci., 13 January 2022

Sec. Neurodegeneration

Volume 15 - 2021 | https://doi.org/10.3389/fnins.2021.747569

Leukoaraiosis and Gray Matter Volume Alteration in Older Adults: The PROOF Study

  • 1. Clinical Physiology, Visas Center, University Hospital, Saint-Etienne, France

  • 2. INSERM, U1059, SAINBIOSE, DVH, Saint-Étienne, France

  • 3. Department of Radiology, University Hospital, Saint Etienne, France

  • 4. EA7423 TAPE, UJM, Saint-Étienne, France

  • 5. Department of Geriatric Medicine and Memory Clinic, Research Center on Autonomy and Longevity, University Hospital, Angers, France

  • 6. UPRES EA4638, University of Angers, Angers, France

Article metrics

View details

10

Citations

5k

Views

1,2k

Downloads

Abstract

Background and Purpose: Leukoaraiosis, also called white matter hyperintensities (WMH), is frequently encountered in the brain of older adults. During aging, gray matter structure is also highly affected. WMH or gray matter defects are commonly associated with a higher prevalence of mild cognitive impairment. However, little is known about the relationship between WMH and gray matter. Our aim was thus to explore the relationship between leukoaraiosis severity and gray matter volume in a cohort of healthy older adults.

Methods: Leukoaraiosis was rated in participants from the PROOF cohort using the Fazekas scale. Voxel-based morphometry was performed on brain scans to examine the potential link between WMH and changes of local brain volume. A neuropsychological evaluation including attentional, executive, and memory tests was also performed to explore cognition.

Results: Out of 315 75-year-old subjects, 228 had punctuate foci of leukoaraiosis and 62 had begun the confluence of foci. Leukoaraiosis was associated with a decrease of gray matter in the middle temporal gyrus, in the right medial frontal gyrus, and in the left parahippocampal gyrus. It was also associated with decreased performances in memory recall, executive functioning, and depression.

Conclusion: In a population of healthy older adults, leukoaraiosis was associated with gray matter defects and reduced cognitive performance. Controlling vascular risk factors and detecting early cerebrovascular disease may prevent, at least in part, dementia onset and progression.

Introduction

Leukoaraiosis is a rarefaction of white matter found on magnetic resonance imaging (MRI) as white matter hyperintensities (WMH) (Hachinski et al., 1987). WMH are commonly observed on brain MRIs in older adults, thus leading some authors to speak of age-related white matter changes.

Although they are considered as silent manifestations of aging, WMH do not only correlate with age but they are also associated with numerous cardiovascular risk factors including hypertension, diabetes mellitus (Scharf et al., 2019; Grosu et al., 2021), and obstructive sleep apnea (Ho et al., 2018). We already reported that, in older untreated prehypertensive patients, increased ambulatory blood pressure (BP) was significantly associated with higher occurrence of leukoaraiosis (Avet et al., 2014), an alteration found with a relative low mean load value of 24-h systolic BP. Such frailty of the peripheral vascular cerebral tree in older adults challenges the general practitioners to apply a more important use of antihypertensive medication in older adults, optimal in fact, and consider the other risk factors of obstructive sleep apnea and diabetes as well. It is noticeable that these three conditions share hypertension as a common risk factor.

Furthermore, leukoaraiosis appears to be deleterious for cognitive functions, resulting in lower hippocampal volume (Triantafyllou et al., 2020) and/or higher prevalence of mild cognitive impairment, Alzheimer’s disease, and dementia (Cai et al., 2015; Alber et al., 2019). The pathophysiological consequences of such alterations in deep brain white matter are still debated. It is proposed that axonal alterations linked to microvascular periventricular occlusion may in turn affect the integrity of neuronal function, with acceleration of cell death in several critical cortical areas. In 2018, Al-Janabi et al. (2018) observed that WMH were one of the major factors explaining global cerebral atrophy. Furthermore, Lambert et al. (2015, 2016) observed significant gray matter (GM) changes linked to WMH. According to Raji et al. (2012), the increase in white matter lesions is related to a decrease in GM volume as well as a decrease in cognition. To our knowledge, the link between WMH, a full exhaustive exploration of cognitive decline, and GM decrease has never been studied in the healthy elderly population.

Hence, our aim in the present study was to refine this three-party relationship between leukoaraiosis severity and GM volume decrease in a cohort representative of the general population aged 75 years and over.

Materials and Methods

Population

The PROgnostic indicator OF cardiovascular and cerebrovascular events (PROOF) study consists of 1,011 healthy older adults homogeneous in age, 65 years, when recruited for inclusion in the city of Saint-Étienne, France (Barthélémy et al., 2007). At inclusion, in 2001, all participants were at low risk of cardiac or cerebrovascular events (2001 timepoint).

In 2009–2011, participants were invited to pass the fourth examination of the study comprising ambulatory BP monitoring and MRI of the brain. More than a half of the 1,011 subjects agreed (2010 time point).

The PROOF study was approved by an Ethics Review Board (CCPRB Rhône-Alpes Loire), and all participants signed a written informed consent for all clinical research procedures.

Ambulatory Blood Pressure Monitoring

Ambulatory blood pressure was monitored on 24 h using a non-invasive auscultatory method (Diasys Integra, Novacor, Rueil-Malmaison, France) at both time points (Avet et al., 2014). Automatic measurements began in the early morning on a weekday and were taken from the non-dominant arm every 15 min during daytime and every 30 min during the night. During the recording, participants were required not to change their habits, including daily activities and sleeping habits.

Clinical systolic and diastolic blood pressures (SBP and DBP, respectively) were also measured and defined as the mean of two consecutive BP measurements obtained with a mercury sphygmomanometer after the subject had been lying down for 15 min.

Average values of 24-h SBP and DBP, and awake and sleep SBP and DBP, were calculated from ambulatory blood pressure monitoring (ABPM). Systolic and diastolic Dip were calculated according to Dip = (awake BP − sleep BP/awake BP); pulse pressure (PP) was defined as PP = 24-h SBP − 24-h DBP; and mean arterial BP (MAP) was obtained from MAP = (24-h SBP + [2 × 24-h DBP])/3).

Brain Magnetic Resonance Imaging

MRI was performed at a second time point with a 1.5-T scanner (Magnetom Avento, Siemens Healthcare, Erlangen, Germany), which had a 12-channel head coil. The acquisition protocol included a 3D T1 magnetization prepared rapid gradient echo (MP-RAGE) with a resolution of 1 × 1 × 1 mm3, repetition time (TR) of 2,060 ms, echo time (TE) of 3.23 ms, inversion time (TI) of 1,100 ms, and acquisition matrix of 256 × 256 and included 176 slices. The protocol also included a T2-weighted, 2D turbo spin echo with a TR of 6,270 ms, TE of 109 ms, acquisition matrix of 448 × 360, and 24 slices which were 5 mm thick. A 2D fluid-attenuated inversion recovery (FLAIR) was also acquired with a TR of 5,000 ms, TE of 350 ms, TI of 1,800 ms, acquisition matrix of 256 × 192, and 52 3-mm-thick slices.

Visual examination of the MRIs lead to the exclusion of scans considered as structurally invalid for a voxel-based morphometry (VBM) study (meningiomas, major lacunas, cysts, sequels of stroke).

Assessment of White Matter Lesions

The degree of white matter lesion severity was rated using the semiquantitative visual age-related white matter changes scale (ARWMC) devised by Fazekas et al. (2002) applied to the T2-weighted FLAIR images. ARWMC was graded on a four-point scale of increasing severity: 0, normal; 1, punctuate foci; 2, beginning confluence of foci; and 3, large confluent areas. The reliability of the Fazekas scale is high with an intraoperator correlation coefficient of 0.85 (Leaper et al., 2001), and MR images were scored by a single neuroradiologist observer (CB) who was blinded to the participants’ clinical information, including age, gender, prior imaging findings, and cardiovascular disease risk factors.

Cognitive Evaluation

Cognitive evaluation was performed using a battery of psychometric tests (Saint Martin et al., 2012). Global intellectual performance was evaluated using the Mini Mental State Examination. Cognitive complaint was investigated with a visual analog scale. We then explored more precisely three cognitive domains: memory, attention and information processing, and executive functioning.

Memory was assessed using the Benton Visual Retention Test (Form C) and the Free and Cued Selective Reminding Test (FCSRT) from Grober & Buschke. Attention and information processing were assessed using the Trail-Making Test Part A (TMTA), the Stroop Color–Word Test, and the coding subtest of the Wechsler Adult Intelligence Scale III (WAIS III). Executive functioning was tested using the Trail-Making Test Part B (TMTB), the Stroop Color–Word Test, an alphabetic fluency test using the letter P, a category fluency test using animal names, and the similarities subtest of the WAIS III.

We also assessed anxiety and depression using the Pichot questionnaire and the French version of the Goldberg scale, respectively. Cognitive function was assessed using the short form of the MacNair scale.

Voxel-Based Morphometry

MRI images were processed according to classical SPM12 protocol using default settings. All images were first segmented using SPM12 segmentation, formerly known as NewSegment method. Gray matter, white matter, and cerebrospinal partitions were visually checked for mis-segmentation. Preregistered segmented white and gray matter images were registered using the DARTEL algorithm after the creation of a template based on all scans. Registered segmented images were normalized to the Montreal Neurological Institute (MNI) space and were finally smoothed with an 8*8*8-mm3 kernel. Mis-registration was visually checked, and a CAT12 check sample homogeneity script was used to focus on the most different images. No subject was excluded after the visual inspections.

Statistical Analysis

For VBM analysis, we performed a multiple linear regression with SPM12: leukoaraiosis was the covariate of interest whereas sex, presence of antihypertensive medications, sociocultural level, and total intracranial volume were introduced in the model as covariates. The statistical threshold was set at p < 0.05 at the family-wise error (FWE)-corrected voxel level with an extent threshold of 250 voxels to have the most significant clusters (p < 0.001 at cluster level).

One-way ANOVA was used to explore the differences of cognitive tests between each level of leukoaraiosis. The Scheffe post hoc test was used to identify which of the three groups were statistically different.

Results

Characteristics of the Population

From the 1,011 subjects included in 2001, five hundred did not have an MRI recording and 90 MRIs were considered as invalid. Eight more subjects were excluded because they did not have the cognition assessment. We had no information about medications in 66 more subjects. Furthermore, 32 refused the ABP monitoring or had invalid data. Three hundred and fifteen participants were finally included in the present analysis (Figure 1).

FIGURE 1

FIGURE 1

Detailed description of the inclusion/exclusion. MRI: magnetic resonance imaging, HT: hypertension, ABPM: ambulatory blood pressure monitoring. *Missing subjects were majorly dead but were also lost from view or withdrew from the study. Others were not eligible for MRI (claustrophobia, pacemaker) or refused MRI.

At the time of the MRI recording, participants were 75.3 ± 0.8 years old and slightly overweight with a BMI of 25.1 ± 3.6. Detailed characteristics of the population are given in Table 1.

TABLE 1

Mean ± SD [Min–Max]
Age (years) 75.3 ± 0.8 [72.3–77.8]
BMI (kg/m2) 25.1 ± 3.6 [15.1–35.8]
Waist circumference (cm) 86.9 ± 10.8 [62–117]
Fasting blood glucose (g/L) 1.0 ± 0.2 [0.7–2.4]
Total cholesterol (g/L) 2.3 ± 0.4 [1.2–3.5]
HDL cholesterol (g/L) 0.7 ± 0.8 [0.3–1.3]
LDL cholesterol (g/L) 1.4 ± 0.3 [0.4–2.4]
LDL/HDL cholesterol 2.1 ± 0.7 [0.3–4.2]
Triglycerides (g/L) 1.1 ± 0.5 [0.4–4.0]
SBP (mmHg) 133.2 ± 19.4 [76–189]
DBP (mmHg) 85.6 ± 15.2 [44–149]
24-h SBP (mmHg) 117.2 ± 13.0 [79–159]
24-h DBP (mmHg) 71.9 ± 7.4 [51–98]
Awake SBP (mmHg) 122.0 ± 13.6 [84–162]
Awake DBP (mmHg) 75.2 ± 8.3 [53–117]
Sleep SBP (mmHg) 106.0 ± 13.9 [69–161]
Sleep DBP (mmHg) 64.7 ± 7.9 [45–87]
Systolic dip (mmHg) 0.1 ± 0.1 [−0.2 –+ 0.3]
Diastolic dip (mmHg) 0.1 ± 0.1 [−0.1 –+ 0.5]
PP (mmHg) 45.3 ± 9.6 [21–78]
MAP (mmHg) 87.0 ± 8.5 [63.0–117.7]

Characteristics of the population.

Age, BMI, waist circumference, SBP, and DBP were available for the 315 subjects. Biological data were available for 288 subjects except LDL, HDL, and LDL/HDL cholesterol (287 subjects). ABPM data were available for 309 subjects except for systolic and diastolic DIP (307 subjects).

BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; MAP, mean arterial pressure; ABPM, ambulatory blood pressure monitoring. Data are presented as mean ± standard deviation.

Leukoaraiosis

Out of the 315 subjects, 25 were rated as normal on the ARWMRC, 228 were rated as having punctuate foci, and 62 were rated as presenting beginning confluence of foci. None had large confluent areas.

Cognition

Leukoaraiosis was mainly associated with differences in memory recall (3-word MMSE recall, total recall, and delayed free recall of the FCSRT) and in executive functioning (TMT-B, Code of the WAIS III) and also associated with depression (Table 2).

TABLE 2

Leukoaraiosis level 0 1 2 p-value
Visual analog scale 2.5 ± 1.6 2.8 ± 1.7 3.0 ± 1.6 ns
MMSE
Total score 28.4 ± 2.2 28.5 ± 1.6 27.8 ± 2.0 <0.05
3-word recall 2.5 ± 0.8 2.7 ± 2.6 2.5 ± 0.8 ns
FCSRT
Immediate recall 15.4 ± 0.9 15.4 ± 1.0 15.1 ± 1.2 ns
Total recall 46.6 ± 1.8 46.2 ± 3.0 44.7 ± 6.6 <0.05
Delayed recall 15.8 ± 0.5 15.7 ± 0.7 15.2 ± 2.3 <0.01
Total free recall 29.2 ± 6.6 29.4 ± 5.8 27.7 ± 7.1 ns
Delayed free recall 11.7 ± 2.4 11.7 ± 2.3 11.1 ± 3.1 ns
Delayed cued recall 4.0 ± 2.4 4.1 ± 2.1 4.2 ± 2.4 ns
Intrusions 0.6 ± 1.0 0.7 ± 1.4 1.3 ± 2. <0.05
Recognition 16.0 ± 0.2 16.0 ± 0.2 15.8 ± 0.7 <0.001
Semantically related intrusions 0 0.0 ± 0.3 0.1 ± 0.9 ns
Unrelated intrusions 0 0.0 ± 0.1 0.0 ± 0.2 ns
Benton test 13.0 ± 1.3 12.6 ± 1.6 12.5 ± 1.6 ns
WAIS-III code test
Score 50.9 ± 9.6 53.6 ± 12.6 49.0 ± 12.8 <0.05
Standardized score 11.0 ± 2.1 11.6 ± 2.6 10.6 ± 2.8 <0.05
Copy score 110.0 ± 23.4 114.2 ± 20.5 110.2 ± 23.9 ns
Trail making test
TMT-A (s) 49.7 ± 15.1 46.9 ± 15.4 49.9 ± 16.6 ns
TMT-A Errors 0.0 ± 0.2 0.1 ± 0.8 0.1 ± 0.2 ns
TMT-B (s) 102.3 ± 33.2 98.7 ± 35.8 114.9 ± 58.7 <0.05
TMT-B Errors 0.2 ± 0.4 0.5 ± 1.0 0.7 ± 1.2 ns
TMT-B–TMT-A (s) 52.6 ± 25.6 51.8 ± 30.3 65.0 ± 49.2 <0.05
Stroop
Word score 89.4 ± 16.9 94.5 ± 13.0 93.0 ± 11.7 ns
Color score 65.9 ± 11.4 66.7 ± 10.7 64.6 ± 8.9 ns
Color–word score 32.3 ± 8.2 32.4 ± 7.9 31.3 ± 9.1 ns
Stroop Interference 3.2 ± 6.6 2.1 ± 6.7 2.1 ± 8.0 ns
Standardized word score 103.4 ± 16.9 108.6 ± 13.0 107.1 ± 11.7 ns
Word z-score −0.1 ± 0.4 −0.1 ± 0.7 −0.1 ± 0.5 ns
Standardized color score 75.9 ± 11.4 77.6 ± 10.7 75.6 ± 8.9 ns
Color z-score −0.6 ± 0.7 −0.3 ± 0.7 −0.3 ± 0.7 ns
Standardized color–word score 47.2 ± 8.3 47.3 ± 7.9 46.3 ± 9.0 ns
Color–word z-score −0.2 ± 0.6 0.1 ± 0.8 −0.4 ± 1.0 ns
Verbal fluency
Semantic 30.2 ± 8.0 30.4 ± 7.3 28.5 ± 7.7 ns
Semantic false answer 0.8 ± 0.9 0.6 ± 1.0 0.5 ± 0.8 ns
Semantic Z-score 0.1 ± 0.9 0.1 ± 0.9 −0.2 ± 1.0 ns
Phonemic 21.0 ± 8.3 20.4 ± 6.3 19.0 ± 6.4 ns
Phonemic false answer 0.6 ± 0.8 0.6 ± 0.9 0.4 ± 0.8 ns
Phonemic Z-score 0.1 ± 1.0 −0.1 ± 0.9 −0.2 ± 0.7 ns
WAIS-III similarities test
Score 19.5 ± 5.4 17.7 ± 5.6 17.1 ± 5.8 ns
Standardized score 12.3 ± 2.4 11.4 ± 2.5 11.2 ± 2.8 ns
Z-score 0.8 ± 0.8 0.5 ± 0.8 0.4 ± 0.9 ns
Cognitive function 25.6 ± 8.7 26.8 ± 11.2 29.3 ± 13.9 ns
Anxiety 2.9 ± 2.6 3.1 ± 2.8 3.0 ± 2.6 ns
Depression 2.0 ± 1.7 2.3 ± 2.4 3.5 ± 3.7 <0.001

Relationship between cognitive tests and leukoaraiosis level using one-way ANOVA.

MMSE, Mini-Mental State Examination; TMT, trail making test; FCRST, Free and Cued Selective Reminding Test. Data are presented as mean ± standard deviation.

Post hoc analyses revealed that cognition was different between level 2 of the leukoaraiosis scale (beginning confluence) and level 1 (punctuate foci) but not between normal WM and level 1.

Voxel-Based Morphometry

Leukoaraiosis severity at time point 4 was inversely correlated with gray matter volume in the right middle temporal gyrus (Brodmann area 21), in the right medial frontal gyrus (Brodmann area 11), and in the left parahippocampal gyrus (Table 3 and Figure 2). Relationships were statistically significant at the cluster level as well as in the corrected voxel level.

TABLE 3

Side Brain region X Y Z Cluster size pclust pvox
R Middle temporal gyrus 54 −8 −22 282 0.001 <0.001
R Medial frontal gyrus 3 33 −14 337 0.001 0.002
L Parahippocampal gyrus −32 −24 −15 265 0.001 0.007

Gray matter decrease associated with an increase in leukoaraiosis score (R: right, L: left, pclust: p-value at the cluster level with a family-wise error (FWE) correction, pvox: p-value at the peak voxel with a FWE correction).

FIGURE 2

FIGURE 2

Gray matter volume decrease in the right middle temporal gyrus (A), right medial frontal gyrus (B), and left parahippocampal gyrus (C).

We did not observe any gray matter increase associated with an increase in leukoaraiosis.

Discussion

The present study confirmed that leukoaraiosis in older adults is associated with a decrease in GM volume in several cortical areas including the right middle temporal gyrus, the right medial frontal gyrus, and the left parahippocampal gyrus. Such decreases remained highly significant after usual corrections for confounders. Moreover, we noticed that higher leukoaraiosis was associated with a decrease in cognitive functions, mainly in memory (total recall) and executive functions (Code of the WAIS III, TMTB).

In 2001, the Leukoaraiosis And DISability (LADIS) study was built to assess the role of white matter changes and their progression on the onset of disability in older adults (The LADIS Study Group, 2011). In 639 non-healthy but functionally autonomous 74-year-old patients, the group demonstrated that WMH were associated with worse score on MMSE (van der Flier, 2005) and worse cognitive performance (Verdelho et al., 2007). However, these subjects had various complaints and disturbances (mild cognitive impairment, motor disturbances, mood disturbances, minor cerebrovascular events, or other neurological problems). Later, the association between WMH and cognitive impairment and/or dementia was confirmed in older adults (94 years old) (Legdeur et al., 2020). A meta-analysis in more than 14,000 participants for WMH showed a link between WMH and dementia/Alzheimer’s disease (AD) (Debette et al., 2019). In 2004, Verdelho et al. (2007) observed an association between WMH and Buschke total recall. We confirmed this association in a healthy 75-year-old population comprising adults without any major cognitive impairment or dementia or cognitive complaint (Capizzano, 2004). The differences observed here are subtle, but they remain statistically significant. Of note, none of the subjects had large confluent areas, as in the publication of Verdelho et al. (2007), while we still noted these significant cognitive variations.

Interestingly, Kim et al. (2020) did not observe any relationship between WMH and cognition on subcortical vascular mild cognitive impairment patients. However, they demonstrated a more rapid cortical thinning in frontal and temporal areas associated with a 3-year WMH progression. Cortical thinning in frontal and temporal areas associated with white matter grade was reported by Raji et al. (2012) as well as a thinning in inferior parietal and parahippocampal areas. For Dickie et al. (2016) WMH were also associated with a cortical thinning within and around the Sylvian fissure. In 2005, van der Flier (2005) from the LADIS study group showed that those with medial temporal atrophy and severe WMH had a fourfold increase in the frequency in mild cognitive deficits. In a meta-analysis by Wang et al. (2021) WMH were also associated with medial temporal lobe atrophy in post-stroke patients. Li et al. (2011) also observed frontal and temporal lobe GM decreases using VBM analysis, as well as decreases in the thalamus and parietal lobe. Several studies reported a link between WMH and hippocampal atrophy in mild cognitive impairment patients (Fiford et al., 2017; Wong et al., 2021). In our study, we also observed a GM volume decrease in similar areas (middle temporal gyrus, medial frontal gyrus) as well as in the parahippocampus. Using linear mixed effect models, van Leijsen and her team explained memory decline in older adults by an interaction between WMH and hippocampus volume (van Leijsen et al., 2019). WMH and hippocampus volume were also both markers of the conversion from normal cognition to mild cognitive impairment in Framingham offsprings (Bangen et al., 2018).

During the past decades, WMH have been associated with the two most common forms of dementia, vascular dementia (VD) and AD. The first form of dementia, VD, is caused by defects in blood supply to the brain which generates lacunae and WMH. The second form of dementia, AD, is a multifactorial neurodegenerative disease whose main risk factors are age, genetic, head injury, and other factors such as high cholesterol or high BP. There is a link between AD and/or dementia and WMH, even after the concomitant effect of age on both pathologies had been dismissed (Sarabia-Cobo et al., 2014; Kao et al., 2019). White matter alterations appear years before the estimated symptomatic onset of the disease in autosomal dominant AD (Lee et al., 2016; Araque Caballero et al., 2018). Rojas et al. (2018) discovered a higher prevalence of WMH in homozygous APOE-ε4 allele carriers aged 45–75 years. In non-genetic forms of AD, this link has been less documented and WMH are only associated with severity of AD. Temporal areas and parahippocampus/hippocampus are the first regions affected in AD. It has been hypothesized that the presence of high WMH and the decrease of gray matter in key brain areas may be viewed as prodromal signs of AD as suggested in the literature (Wolf et al., 2000; Vermeer et al., 2003; Prins et al., 2004). It is of importance to note that our population is highly selected: among the 1,011 healthy participants included in 2001, the 315 participants remaining in this sub-study are probably the healthiest part of the population. Thus, they have shown few WMH and they mainly do not have cognitive impairment. None of these participants suffers from dementia, and we do not yet know whether those with poor cognitive results will convert to dementia or not. Future time points of our study should answer this specific question.

WMH are associated with hypertension, dyslipidemia, or diabetes, suggesting a vascular origin of leukoaraiosis in which hypertension seems to play a major key role (Moroni et al., 2016). As a manifestation of cerebral small vessel disease, leukoaraiosis seems to develop gradually and be the “tip of the iceberg” according to de Groot et al. (2013). Conventional MRI techniques may be not sensible enough to detect the first brain disorders: Altamura et al. (2016) observed on MRIs that even in patients with normal-appearing white matter, higher regional apparent water diffusion coefficients were associated with microcirculatory impairment and altered cognitive domain. It thus seems that WMH can originate from cerebral blood flow decrease (Bernbaum et al., 2015). In a previous study, we observed a linear relationship between leukoaraiosis and BP in untreated for hypertension patients, but not in patients treated for hypertension (Avet et al., 2014), which can suggest that controlling hypertension could lower WMH burden.

However, in our study we only assessed WMH using the Fazekas scale, one among multiple ways to define WMH (Frey et al., 2019). Measurements of WMH volumes or local variations of WMH may bring sharper results. Moreover, we were unable to evaluate the status of our population regarding microbleeds.

As a conclusion, WMH are associated with cognitive impairment and brain GM defects in healthy older adults. As WMH find their origin in cerebrovascular impairment, this result strengthens the assumption by Sudo et al. (2015) that controlling vascular risk factors and detecting early cerebrovascular diseases may prevent, at least in part, dementia onset and progression. Further interventional studies implying the strict control of vascular risk factors and their impact on the brain and dementia should confirm this conclusion.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Statements

Data availability statement

The generated datasets may be available after a motivated request to the research team. Requests to access the datasets should be directed to FR.

Ethics statement

The studies involving human participants were reviewed and approved by the CCPRB Rhône-Alpes Loire. The patients/participants provided their written informed consent to participate in this study.

Author contributions

SC and CB contributed to the analysis and interpretation of data. J-CB and FR contributed to the conception and design of the study. SC drafted the manuscript. All authors critically revised the draft.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  • 1

    Alber J. Alladi S. Bae H. J. Barton D. A. Beckett L. A. Bell J. M. et al (2019). White matter hyperintensities in Vascular Contributions to Cognitive Impairment and Dementia (VCID): knowledge gaps and opportunities.Alzheimers Dement.5107117. 10.1016/j.trci.2019.02.001

  • 2

    Al-Janabi O. M. Panuganti P. Abner E. L. Bahrani A. A. Murphy R. Bardach S. H. et al (2018). Global cerebral atrophy detected by routine imaging: relationship with age, hippocampal atrophy, and white matter hyperintensities.J. Neuroimaging28301306. 10.1111/jon.12494

  • 3

    Altamura C. Scrascia F. Quattrocchi C. C. Errante Y. Gangemi E. Curcio G. et al (2016). Regional MRI diffusion, white-matter hyperintensities, and cognitive function in alzheimer’s disease and vascular dementia.J. Clin. Neurol.12:201. 10.3988/jcn.2016.12.2.201

  • 4

    Araque Caballero M. Á Suárez-Calvet M. Duering M. Franzmeier N. Benzinger T. Fagan A. M. et al (2018). White matter diffusion alterations precede symptom onset in autosomal dominant alzheimer’s disease.Brain14130653080. 10.1093/brain/awy229

  • 5

    Avet J. Pichot V. Barthélémy J. C. Laurent B. Garcin A. Roche F. et al (2014). Leukoaraiosis and ambulatory blood pressure load in a healthy elderly cohort study: the PROOF study.Int. J. Cardiol.1725963. 10.1016/j.ijcard.2013.11.052

  • 6

    Bangen K. J. Preis S. R. Delano-Wood L. Wolf P. A. Libon D. J. Bondi M. W. et al (2018). Baseline white matter hyperintensities and hippocampal volume are associated with conversion from normal cognition to mild cognitive impairment in the framingham offspring study.Alzheimer Dis. Assoc. Disord.325056. 10.1097/WAD.0000000000000215

  • 7

    Barthélémy J. C. Pichot V. Dauphinot V. Celle S. Laurent B. Garcin A. et al (2007). Autonomic nervous system activity and decline as prognostic indicators of cardiovascular and cerebrovascular events: the “PROOF” study. study design and population sample. associations with sleep-related breathing disorders: the “SYNAPSE” study.Neuroepidemiology291828. 10.1159/000108914

  • 8

    Bernbaum M. Menon B. K. Fick G. Smith E. E. Goyal M. Frayne R. et al (2015). Reduced blood flow in normal white matter predicts development of leukoaraiosis.J. Cereb. Blood Flow Metab.3516101615. 10.1038/jcbfm.2015.92

  • 9

    Cai Z. Wang C. He W. Tu H. Tang Z. Xiao M. et al (2015). Cerebral small vessel disease and alzheimers disease.Clin. Interv. Aging1016951704. 10.2147/CIA.S90871

  • 10

    Capizzano A. A. (2004). White matter hyperintensities are significantly associated with cortical atrophy in alzheimer’s disease.J. Neurol. Neurosurg. Psychiatry75822827. 10.1136/jnnp.2003.019273

  • 11

    de Groot M. Verhaaren B. F. de Boer R. Klein S. Hofman A. van der Lugt A. et al (2013). Changes in normal-appearing white matter precede development of white matter lesions.Stroke4410371042. 10.1161/STROKEAHA.112.680223

  • 12

    Debette S. Schilling S. Duperron M. G. Larsson S. C. Markus H. S. (2019). Clinical significance of magnetic resonance imaging markers of vascular brain injury: a systematic review and meta-analysis.JAMA Neurol.7681. 10.1001/jamaneurol.2018.3122

  • 13

    Dickie D. A. Karama S. Ritchie S. J. Cox S. R. Sakka E. Royle N. A. et al (2016). Progression of white matter disease and cortical thinning are not related in older community-dwelling subjects.Stroke47410416. 10.1161/STROKEAHA.115.011229

  • 14

    Fazekas F. Barkhof F. Wahlund L. O. Pantoni L. Erkinjuntti T. Scheltens P. et al (2002). CT and MRI rating of white matter lesions.Cerebrovasc. Dis.133136. 10.1159/000049147

  • 15

    Fiford C. M. Manning E. N. Bartlett J. W. Cash D. M. Malone I. B. Ridgway G. R. et al (2017). White matter hyperintensities are associated with disproportionate progressive hippocampal atrophy: association of wmh with hippocampal atrophy.Hippocampus27249262. 10.1002/hipo.22690

  • 16

    Frey B. M. Petersen M. Mayer C. Schulz M. Cheng B. Thomalla G. (2019). Characterization of white matter hyperintensities in large-scale MRI-studies.Front. Neurol.10:238. 10.3389/fneur.2019.00238

  • 17

    Grosu S. Rospleszcz S. Hartmann F. Habes M. Bamberg F. Schlett C. L. et al (2021). Associated factors of white matter hyperintensity volume: a machine-learning approach.Sci. Rep.11:2325. 10.1038/s41598-021-81883-4

  • 18

    Hachinski V. C. Potter P. Merskey H. (1987). Leuko-araiosis.Arch. Neurol.442123. 10.1001/archneur.1987.00520130013009

  • 19

    Ho B. L. Tseng P. T. Lai C. L. Wu M. N. Tsai M. J. Hsieh C. F. et al (2018). Obstructive sleep apnea and cerebral white matter change: a systematic review and meta-analysis.J. Neurol.26516431653. 10.1007/s00415-018-8895-7

  • 20

    Kao Y. H. Chou M. C. Chen C. H. Yang Y. H. (2019). White matter changes in patients with alzheimer’s disease and associated factors.J. Clin. Med.8:167. 10.3390/jcm8020167

  • 21

    Kim S. J. Lee D. K. Jang Y. K. Jang H. Kim S. E. Cho S. H. et al (2020). The effects of longitudinal white matter hyperintensity change on cognitive decline and cortical thinning over three years.J. Clin. Med.9:2663. 10.3390/jcm9082663

  • 22

    Lambert C. Benjamin P. Zeestraten E. Lawrence A. J. Barrick T. R. Markus H. S. (2016). Longitudinal patterns of leukoaraiosis and brain atrophy in symptomatic small vessel disease.Brain13911361151. 10.1093/brain/aww009

  • 23

    Lambert C. Sam Narean J. Benjamin P. Zeestraten E. Barrick T. R. Markus H. S. (2015). Characterising the grey matter correlates of leukoaraiosis in cerebral small vessel disease.NeuroImage Clin.9194205. 10.1016/j.nicl.2015.07.002

  • 24

    Leaper S. A. Murray A. D. Lemmon H. A. Staff R. T. Deary I. J. Crawford J. R. et al (2001). Neuropsychologic correlates of brain white matter lesions depicted on MR images: 1921 aberdeen birth cohort.Radiology2215155. 10.1148/radiol.2211010086

  • 25

    Lee S. Viqar F. Zimmerman M. E. Narkhede A. Tosto G. Benzinger T. L. et al (2016). White matter hyperintensities are a core feature of alzheimer’s disease: evidence from the dominantly inherited alzheimer network: white matter hyperintensities in familial AD.Ann. Neurol.79929939. 10.1002/ana.24647

  • 26

    Legdeur N. Badissi M. Yaqub M. Beker N. Sudre C. H. Ten Kate M. et al (2020). What determines cognitive functioning in the oldest-old? The EMIF-AD 90+ study. J. Gerontol. B Psychol. Sci. Soc. Sci.76, 14991511. 10.1093/geronb/gbaa152

  • 27

    Li C. Du H. Zheng J. Wang J. (2011). A voxel-based morphometric analysis of cerebral gray matter in subcortical ischemic vascular dementia patients and normal aged controls.Int. J. Med. Sci.8482486. 10.7150/ijms.8.482

  • 28

    Moroni F. Ammirati E. Magnoni M. D’Ascenzo F. Anselmino M. Anzalone N. et al (2016). Carotid atherosclerosis, silent ischemic brain damage and brain atrophy: a systematic review and meta-analysis.Int. J. Cardiol.223681687. 10.1016/j.ijcard.2016.08.234

  • 29

    Prins N. D. van Dijk E. J. den Heijer T. Vermeer S. E. Koudstaal P. J. Oudkerk M. et al (2004). Cerebral white matter lesions and the risk of dementia.Arch. Neurol.61:1531. 10.1001/archneur.61.10.1531

  • 30

    Raji C. A. Lopez O. L. Kuller L. H. Carmichael O. T. Longstreth W. T. Jr. Gach H. M. et al (2012). White matter lesions and brain gray matter volume in cognitively normal elders.Neurobiol. Aging33834.e716. 10.1016/j.neurobiolaging.2011.08.010

  • 31

    Rojas S. Brugulat-Serrat A. Bargalló N. Minguillón C. Tucholka A. Falcon C. et al (2018). Higher prevalence of cerebral white matter hyperintensities in homozygous APOE-ε4 allele carriers aged 45–75: results from the ALFA study.J. Cereb. Blood Flow Metab.38250261. 10.1177/0271678X17707397

  • 32

    Saint Martin M. Sforza E. Barthélémy J. C. Thomas-Anterion C. Roche F. (2012). Does subjective sleep affect cognitive function in healthy elderly subjects?Proof Cohort. Sleep Med.1311461152. 10.1016/j.sleep.2012.06.021

  • 33

    Sarabia-Cobo C. M. Pérez V. Hermosilla C. Nuñez M. J. de Lorena P. (2014). Apathy and leukoaraiosis in mild cognitive impairment and alzheimer’s disease: multicenter diagnostic criteria according to the latest studies.Dement. Geriatr. Cogn. Dis. Extra4228235. 10.1159/000363227

  • 34

    Scharf E. L. Graff-Radford J. Przybelski S. A. Lesnick T. G. Mielke M. M. Knopman D. S. et al (2019). Cardiometabolic health and longitudinal progression of white matter hyperintensity: the mayo clinic study of aging.Stroke5030373044. 10.1161/STROKEAHA.119.025822

  • 35

    Sudo F. K. Alves G. S. Tiel C. Ericeira-Valente L. Moreira D. M. Laks J. (2015). Neuroimaging criteria and cognitive performance in vascular mild cognitive impairment: a systematic review.Dement. Neuropsychol.9394404. 10.1590/1980-57642015DN94000394

  • 36

    The LADIS Study Group (2011). 2001–2011: a decade of the LADIS (Leukoaraiosis And DISability) study: what have we learned about white matter changes and small-vessel disease?Cerebrovasc. Dis.32577588. 10.1159/000334498

  • 37

    Triantafyllou A. Ferreira J. P. Kobayashi M. Micard E. Xie Y. Kearney-Schwartz A. et al (2020). Longer duration of hypertension and MRI microvascular brain alterations are associated with lower hippocampal volumes in older individuals with hypertension.J. Alzheimers Dis.74227235. 10.3233/JAD-190842

  • 38

    van der Flier W. M. (2005). Medial Temporal lobe atrophy and white matter hyperintensities are associated with mild cognitive deficits in non-disabled elderly people: the LADIS study.J. Neurol. Neurosurg. Psychiatry7614971500. 10.1136/jnnp.2005.064998

  • 39

    van Leijsen E. M. C. Tay J. van Uden I. W. M. Kooijmans E. C. M. Bergkamp M. I. van der Holst H. M. et al (2019). Memory decline in elderly with cerebral small vessel disease explained by temporal interactions between white matter hyperintensities and hippocampal atrophy.Hippocampus29500510. 10.1002/hipo.23039

  • 40

    Verdelho A. Madureira S. Ferro J. M. Basile A. M. Chabriat H. Erkinjuntti T. et al (2007). Differential impact of cerebral white matter changes, diabetes, hypertension and stroke on cognitive performance among non-disabled elderly. the LADIS study.J. Neurol. Neurosurg. Psychiatry7813251330. 10.1136/jnnp.2006.110361

  • 41

    Vermeer S. E. Prins N. D. den Heijer T. Hofman A. Koudstaal P. J. Breteler M. M. (2003). Silent brain infarcts and the risk of dementia and cognitive decline.N. Engl. J. Med.34812151222. 10.1056/NEJMoa022066

  • 42

    Wang F. Hua S. Zhang Y. Yu H. Zhang Z. Zhu J. et al (2021). Association between small vessel disease markers, medial temporal lobe atrophy and cognitive impairment after stroke: a systematic review and meta-analysis.J. Stroke Cerebrovasc. Dis.30:105460. 10.1016/j.jstrokecerebrovasdis.2020.105460

  • 43

    Wolf H. Ecke G. M. Bettin S. Dietrich J. Gertz H. J. (2000). Do white matter changes contribute to the subsequent development of dementia in patients with mild cognitive impairment? A longitudinal study.Int. J. Geriatr. Psychiatry15803812. 10.1002/1099-1166(200009)15:9<803::aid-gps190>3.0.co;2-w

  • 44

    Wong F. C. C. Yatawara C. Low A. Foo H. Wong B. Y. X. Lim L. et al (2021). Cerebral small vessel disease influences hippocampal subfield atrophy in mild cognitive impairment.Transl. Stroke Res.12284292. 10.1007/s12975-020-00847-4

Summary

Keywords

leukoaraiosis, aging, voxel based morphometry, cognition, vascular risk factors

Citation

Celle S, Boutet C, Annweiler C, Ceresetti R, Pichot V, Barthélémy J-C and Roche F (2022) Leukoaraiosis and Gray Matter Volume Alteration in Older Adults: The PROOF Study. Front. Neurosci. 15:747569. doi: 10.3389/fnins.2021.747569

Received

26 July 2021

Accepted

22 November 2021

Published

13 January 2022

Volume

15 - 2021

Edited by

Scott Edward Counts, Michigan State University, United States

Reviewed by

Omar M. Al-Janabi, University of Kentucky HealthCare, United States; Cheryl R. McCreary, University of Calgary, Canada

Updates

Copyright

*Correspondence: Sébastien Celle,

This article was submitted to Neurodegeneration, a section of the journal Frontiers in Neuroscience

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics